Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Taxane chemotherapy with lapatinib or trastuzumab as first-line therapy for HER2-positive metastatic breast cancer
jRCT2080220643Phase 3Completed
- Sponsor
- Novartis
- Start
- Dec 2008
- Modality
- Monoclonal Antibodies → Antibody-Based Therapeutics, Small Molecules
01
Overview
Phase 3, randomised, open-label trial in HER2-enriched breast cancer (HER2+) comparing Taxane-based chemotherapy + lapatinib with Taxane-based chemotherapy + trastuzumab (2 arms). Started Dec 2008; status: completed.
02
Drugs
lapatinibtrastuzumab
03
Conditions
HER2-enriched breast cancer (HER2+)
Beyond the preview
Go deeper on jRCT2080220643.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on jRCT2080220643.